Table 2.
Author | System | Approach | Target | Utility for diseases | Reference number |
---|---|---|---|---|---|
Wei Ren et al. | Lung diseases | Treating with IL-22 and/or AG490 | PMVEC apoptosis mediated by AngII through activating the JAK2/STAT3 signaling pathway |
Aortic dissection with acute lung injury | 45 |
Minrui Liang et al. | Lung diseases | Administration of recombinant human IL-22 |
Amelioration of epithelial to mesenchymal transition and partial reversion of the impaired cell viability |
bleomycin- induced pulmonary fibrosis | 47 |
Philip L. Simonian et al. | Lung diseases | Preventing expression of IL-22 either by mutating AhR or inhibiting AhR signalling, direct blockade of IL-22 and administration of recombinant IL-22 |
AhR signaling pathway in γδT cells and recruitment of CD4+T cells to lung | hypersensitivity pneumonitis that progresses to lung fibrosis upon repeated exposure to the ubiquitous microorganism Bacillus subtilis |
48 |
Jill R Johnson et al. | Lung diseases | Injection of IL-22+ TGF-β1 | Increased expression of some EMT transcription factors (Snail1 and Zeb1) |
Asthma | 49 |
Heather M. McGee et al. | Skin diseases | IL-22−/− mice | IL-22 directs extracellular matrix gene expression as well as myofibroblast differentiation both in vitro and in vivo. | Acute skin wounding repair | 50 |
Geethanjali Pickert et al. | Intestine diseases | STAT3IEC-KO mice | STAT3 regulates the cellular stress response, apoptosis, and pathways associated with wound healing in IECs. | Mucosal wound healing in intestine | 28 |
Caroline A. Lindemans et al. | Intestine diseases | Administration of recombinant IL-22 | Recombinant IL-22 directly targeted ISCs, augmenting the growth of both murine and human intestinal organoids, increasing proliferation, and promoting ISC expansion. | Graft vs. host disease in intestine after murine allogeneic bone marrow transplantation | 22 |
Fangchen Gong et al. | Cardiac diseases | Blocking of IL-22R1 with IL-22R1 antibody |
IL-22 was found to protect endothelial cells from glucose- and LPC- induced injury. | Type 2 diabetes mellitus and coronary artery disease | 4 |
Yujie Guo et al. | Cardiac diseases | Administration of anti-IL-22 neutralizing antibody | Treatment of acute viral myocarditis and chronic myocarditis mice with an anti-IL-22 Ab decreased the survival rate and exacerbated myocardial fibrosis. | CVB3-induced chronic myocarditis and dilated cardiomyopathy |
51 |
Svetlana Radaeva et al. | Liver diseases | IL-22 blockade with a neutralizing antibody and injection of recombinant IL-22 | Blocking STAT3 activation abolishes the antiapoptotic and mitogenic actions in hepatic cells. | T cell-mediated hepatitis induced by concanavalin A | 52 |
Ogyi Park et al. | Liver diseases | Liver-specific IL-22 transgenic mice | Complete resistance to concanavalin A–induced T cell hepatitis with minimal effect on liver inflammation and acceleration of liver regeneration after partial hepatectomy |
Concanavalin A–induced T cell hepatitis | 53 |
Zenewicz LA et al. | Liver diseases | IL-22-deficient mice | Protection to hepatocytes injury during acute liver inflammation | Acute liver inflammation | 54 |
Christophe Paget et al. | Infectious | IL-22−/- C57BL/6 mice | DC maturation in response to IAV could lead to IL-22 release by iNKT cells. |
Influenza A Virus Infection | 55 |
Qing Kong et al. | Infectious | Administration of anti-IL-22 neutralizing antibody | Anti-IL-22 Antibody decreased the frequencies of Th22 cells and the levels of IL-22, and increased the expressions of cardiac IL-22R1 and neutralization of IL-22 significantly promoted cardiac viral replication. | Coxsackievirus B3-Induced mice acute viral myocarditis |
56 |
Andrea Sommer et al. | Nutrition | Vitamin D treatment of DCs | The differentiation of IL-22-producing T cells mediated by supernatants of vitamin D-treated DCs was dependent on TNF-α IL-6 and IL-23. | – – – – | 57 |
Yong Woo Ji et al. | Eye diseases | IL-22 knock-out mice | IL-22 is essential for suppression of ocular surface infiltration of Th17 cells and inhibition of dry eye disease induction. | Dry eye disease | 58 |
Minling Hu et al. | Autophagy | Administration of recombinant IL-22 | Both treatment with IL-22 or 3-MA can partly reverse increased levels of ROS and the overexpression of GRP78 and CHOP induced by Palmitate. | – – – – | 59 |